DISCLOSURES Past performance is not indicative of future results. Mention of companies/stocks herein is for illustrative purposes only and should not be interpreted as...
Dear International Growth Fund Shareholder: Baron International Growth Fund® (BINIX, the Fund) gained 8.07% (Institutional Shares) during the third quarter of 2024, while its...
Welcome to another installment of our CEF Market Weekly Review, where we discuss closed-end fund (“CEF”) market activity from both the bottom-up – highlighting...
Five companies priced IPOs this week, led by Birkenstock’s (BIRK) $1.5 billion offering. Three small issuers submitted initial filings. Birkenstock priced its IPO just...
GREETINGS FELLOW SHAREHOLDER The calendar third quarter of 2023 was overall a messy one for financial markets at large, and not particularly fun for...
ByYan Carrière-Swallow, Deputy Division Chief, IMF’s Asia and Pacific Department, and Krishna Srinivasan, Director of Asia and Pacific Department (APD) The region is likely...
Investment Thesis Barclays PLC (NYSE:BCS) share prices appear to have plateaued recently. In my view, this could be due to the reorganization that is...
By Seema Shah, Chief Global Strategist The September Consumer Price Index (CPI) showed that inflation continues to edge towards the Federal Reserve’s (Fed’s) 2%...
The WisdomTree U.S. Efficient Core Fund (NYSEARCA:NTSX) is an interest asset allocation fund that effectively provides 1.5x leveraged returns to the traditional 60/40 portfolio....
Intro Relmada Therapeutics (NASDAQ:RLMD) is advancing its NMDA antagonist, REL-1017 (esmethadone), as a novel antidepressant for the treatment of major depressive disorder (MDD). After...